214 related articles for article (PubMed ID: 25238053)
1. Gankyrin is a predictive and oncogenic factor in well-differentiated and dedifferentiated liposarcoma.
Hwang JA; Yang HM; Hong DP; Joo SY; Choi YL; Park JH; Lazar AJ; Pollock RE; Lev D; Kim SJ
Oncotarget; 2014 Oct; 5(19):9065-78. PubMed ID: 25238053
[TBL] [Abstract][Full Text] [Related]
2. Increased H3K9me3 drives dedifferentiated phenotype via KLF6 repression in liposarcoma.
Keung EZ; Akdemir KC; Al Sannaa GA; Garnett J; Lev D; Torres KE; Lazar AJ; Rai K; Chin L
J Clin Invest; 2015 Aug; 125(8):2965-78. PubMed ID: 26193637
[TBL] [Abstract][Full Text] [Related]
3. An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors.
Peng T; Zhang P; Liu J; Nguyen T; Bolshakov S; Belousov R; Young ED; Wang X; Brewer K; López-Terrada DH; Oliveira AM; Lazar AJ; Lev D
Lab Invest; 2011 Mar; 91(3):392-403. PubMed ID: 21060307
[TBL] [Abstract][Full Text] [Related]
4. Expression of the preadipocyte marker ZFP423 is dysregulated between well-differentiated and dedifferentiated liposarcoma.
Dang TN; Tiongco RP; Brown LM; Taylor JL; Lyons JM; Lau FH; Floyd ZE
BMC Cancer; 2022 Mar; 22(1):300. PubMed ID: 35313831
[TBL] [Abstract][Full Text] [Related]
5. AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas.
May CD; Garnett J; Ma X; Landers SM; Ingram DR; Demicco EG; Al Sannaa GA; Vu T; Han L; Zhang Y; Kivlin CM; Bolshakov S; Kalam AA; Liu J; Zhou F; Broccoli D; Wang WL; Lazar AJ; Pollock RE; Lev D; Torres KE
BMC Cancer; 2015 Nov; 15():901. PubMed ID: 26573603
[TBL] [Abstract][Full Text] [Related]
6. Differential diagnosis of atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma: utility of p16 in combination with MDM2 and CDK4 immunohistochemistry.
Kammerer-Jacquet SF; Thierry S; Cabillic F; Lannes M; Burtin F; Henno S; Dugay F; Bouzillé G; Rioux-Leclercq N; Belaud-Rotureau MA; Stock N
Hum Pathol; 2017 Jan; 59():34-40. PubMed ID: 27597521
[TBL] [Abstract][Full Text] [Related]
7. SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.
Bill KL; Garnett J; Meaux I; Ma X; Creighton CJ; Bolshakov S; Barriere C; Debussche L; Lazar AJ; Prudner BC; Casadei L; Braggio D; Lopez G; Zewdu A; Bid H; Lev D; Pollock RE
Clin Cancer Res; 2016 Mar; 22(5):1150-60. PubMed ID: 26475335
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the 12q amplicons in lipomatous soft tissue tumors by multiplex ligation-dependent probe amplification-based copy number analysis.
Creytens D; Van Gorp J; Speel EJ; Ferdinande L
Anticancer Res; 2015 Apr; 35(4):1835-42. PubMed ID: 25862836
[TBL] [Abstract][Full Text] [Related]
9. MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action.
Somaiah N; Tap W
Cancer Treat Rev; 2024 Jan; 122():102668. PubMed ID: 38104352
[TBL] [Abstract][Full Text] [Related]
10. Aberrant AKT activation drives well-differentiated liposarcoma.
Gutierrez A; Snyder EL; Marino-Enriquez A; Zhang YX; Sioletic S; Kozakewich E; Grebliunaite R; Ou WB; Sicinska E; Raut CP; Demetri GD; Perez-Atayde AR; Wagner AJ; Fletcher JA; Fletcher CD; Look AT
Proc Natl Acad Sci U S A; 2011 Sep; 108(39):16386-91. PubMed ID: 21930930
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of the MDM2/HMGA2 ratio and histological tumor grade in dedifferentiated liposarcoma.
Yamashita K; Kohashi K; Yamada Y; Akatsuka S; Ikuta K; Nishida Y; Toyokuni S; Oda Y
Genes Chromosomes Cancer; 2021 Jan; 60(1):26-37. PubMed ID: 33111425
[TBL] [Abstract][Full Text] [Related]
12. Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation.
Zuco V; Pasquali S; Tortoreto M; Brich S; Percio S; Dagrada GP; Colombo C; Sanfilippo R; Lauricella C; Gounder M; El Bezawy R; Barisella M; Dei Tos AP; Casali PG; Gronchi A; Stacchiotti S; Zaffaroni N
J Exp Clin Cancer Res; 2021 Mar; 40(1):83. PubMed ID: 33648535
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic alteration of p16INK4a gene in dedifferentiation of liposarcoma.
He M; Aisner S; Benevenia J; Patterson F; Harrison LE; Hameed M
Pathol Res Pract; 2009; 205(6):386-94. PubMed ID: 19186005
[TBL] [Abstract][Full Text] [Related]
14. Establishment and characterization of NCC-DDLPS3-C1: a novel patient-derived cell line of dedifferentiated liposarcoma.
Tsuchiya R; Yoshimatsu Y; Noguchi R; Ono T; Sei A; Takeshita F; Sugaya J; Fukushima S; Yoshida A; Ohtori S; Kawai A; Kondo T
Hum Cell; 2021 May; 34(3):1008-1018. PubMed ID: 33677797
[TBL] [Abstract][Full Text] [Related]
15. Update on genomic and molecular landscapes of well-differentiated liposarcoma and dedifferentiated liposarcoma.
Lu J; Wood D; Ingley E; Koks S; Wong D
Mol Biol Rep; 2021 Apr; 48(4):3637-3647. PubMed ID: 33893924
[TBL] [Abstract][Full Text] [Related]
16. Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours.
Aleixo PB; Hartmann AA; Menezes IC; Meurer RT; Oliveira AM
J Clin Pathol; 2009 Dec; 62(12):1127-35. PubMed ID: 19946100
[TBL] [Abstract][Full Text] [Related]
17. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
[TBL] [Abstract][Full Text] [Related]
18. Adipogenesis induces growth inhibition of dedifferentiated liposarcoma.
Kim YJ; Yu DB; Kim M; Choi YL
Cancer Sci; 2019 Aug; 110(8):2676-2683. PubMed ID: 31069877
[TBL] [Abstract][Full Text] [Related]
19. Correlation of histological grade of dedifferentiation with clinical outcome in 55 patients with dedifferentiated liposarcomas.
Dantey K; Schoedel K; Yergiyev O; Bartlett D; Rao UNM
Hum Pathol; 2017 Aug; 66():86-92. PubMed ID: 28300575
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of HURP inhibits the proliferation of hepacellular carcinoma cells via downregulation of gankyrin and accumulation of p53.
Kuo TC; Chang PY; Huang SF; Chou CK; Chao CC
Biochem Pharmacol; 2012 Mar; 83(6):758-68. PubMed ID: 22230478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
